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Abstract
Background: Sulphadoxine-pyrimethamine (SP) a widely used treatment for uncomplicated malaria and recommended for
intermittent preventive treatment of malaria in pregnancy, is being investigated for intermittent preventive treatment of
malaria in infants (IPTi). High levels of drug resistance to SP have been reported from north-eastern Tanzania associated with
mutations in parasite genes. This study compared the in vivo efficacy of SP in symptomatic 6–59 month children with
uncomplicated malaria and in asymptomatic 2–10 month old infants.
Methodology and Principal Findings: An open label single arm (SP) standard 28 day in vivo WHO antimalarial efficacy
protocol was used in 6 to 59 months old symptomatic children and a modified protocol used in 2 to 10 months old
asymptomatic infants. Enrolment was stopped early (87 in the symptomatic and 25 in the asymptomatic studies) due to the
high failure rate. Molecular markers were examined for recrudescence, re-infection and markers of drug resistance and a
review of literature of studies looking for the 581G dhps mutation was carried out. In symptomatic children PCR-corrected
early treatment failure was 38.8% (95% CI 26.8–50.8) and total failures by day 28 were 82.2% (95% CI 72.5–92.0). There was
no significant difference in treatment failures between asymptomatic and symptomatic children. 96% of samples carried
parasites with mutations at codons 51, 59 and 108 in the dhfr gene and 63% carried a double mutation at codons 437 and
540. 55% carried a third mutation with the addition of a mutation at codon 581 in the dhps gene. This triple: triple haplotype
maybe associated with earlier treatment failure.
Conclusion: In northern Tanzania SP is a failed drug for treatment and its utility for prophylaxis is doubtful. The study found
a new combination of parasite mutations that maybe associated with increased and earlier failure.
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Introduction
Sulphadoxine-pyrimethamine (SP) is one of the most widely
used antimalarials worldwide. It is used as first line treatment for
uncomplicated malaria alone or in combination with other
antimalarials, although it has been replaced with other antima-
larials in Southeast Asia and sub-Sahran Africa because of high
levels of resistance. SP is also recommended for use as Intermittent
Preventive Treatment of malaria in pregnancy (IPTp)[1] in sub-
Saharan Africa and is currently being investigated for use as
Intermittent Preventive Treatment of malaria in infants (IPTi)[2].
SP has been used in North-eastern Tanzania since the early
nineteen nineties[3] and was adopted as the first line antimalarial
for uncomplicated malaria nationally in 2001[4]. Plasmodium
falciparum resistance to SP has been recorded in Muheza, north-
eastern Tanzania since 1994[5,6] and 1995[7] and when SP was
adopted as the first line drug the adequate clinical and
parasitological response (ACPR) by day 14 had already fallen to
76% in Tanga region, Tanzania[8]. As part of an ongoing trial of
IPTi using SP, mefloquine and chlorproguanil-dapsone in this
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region, we evaluated the in vivo efficacy of SP in clearing parasites
(clinical efficacy) in order to understand the relationship between
the clinical efficacy and the protective efficacy of SP-IPTi
Traditionally, antimalarial drug efficacy is measured using the
standard WHO 28 day in vivo protocol[9] in symptomatic, 6–
59 month old children. However, results obtained in this
population may not be representative of the efficacy of a drug
when used for prevention. When used for prevention, antimalar-
ials work both by preventing new blood stage infections, the
prophylactic effect, as well as by clearing parasites present in those
who are asymptomatic but infected with malaria[10]. Since
asymptomatic subjects generally have a lower level of parasitaemia
than clinical cases[11] even failing antimalarials may be effective
at clearing parasitaemia in asymptomatic subjects as these
individuals are likely to have some degree of naturally acquired
immunity. Therefore, we have studied the in vivo efficacy of SP in
both symptomatic 6–59 month old children and asymptomatic 2–
10 month old children, the target group for IPTi.
Parasite susceptibility to SP is influenced by mutations in two
genes. Resistance to pyrimethamine is determined by point
mutations at codons 16, 50, 51, 59, 108 and 164 of the dhfr
gene[12,13] and resistance to sulphadoxine by mutations at
codons 436, 437, 540, 581 and 613 of the dhps gene[14,15]. In
Africa, the presence of three dhfr mutations (N51I, C59R, S108N)
together with two dhps mutations (A437G, K540E) prior to
treatment is a significant predictor of SP P. falciparum treatment
failure[16,17,18]. A mutation at codon 164 in the dhfr gene
became established in south east Asia twenty years ago and was
found to be associated with a high level SP resistance, as well as
resistance to chlorproguanil-dapsone[19] and artesunate-dapsone-
proguanil[20]. 164 mutants have recently begun to emerge in
Africa although it is not yet clear that these mutations herald the
emergence the same highly resistant phenotype in-
vivo[21,22,23,24]. Because of the association of mutations in the
dhfr and dhps genes with resistance to SP we studied, molecular
markers in symptomatic children and asymptomatic infants who
had parasitological failures.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Study site
The study was conducted in Hale Health Centre, Tanga
Region, situated 32 km north of Muheza where SP resistance was
first observed in Tanzania. The district experiences perennial,
holoendemic malaria although, in recent years, transmission
appears to have declined substantially. The entomological
inoculation rate from the neighbouring district of Muheza was
148 infectious bites per person per year in 2000[25]. The study site
was chosen due to its proximity to the site of a clinical trial of IPTi
comparing SP, chlorproguanil-dapsone and mefloquine. The
study protocol was approved by the Ethics Review Committees
of the National Institute of Medical Research of Tanzania and the
London School of Hygiene and Tropical Medicine and was
registered as a clinical trial with the National Institute of Health
(Clinicaltrials.gov identifier NCT00361114). The protocol includ-
ed an arm for chlorproguanil/dapsone in the 6–59 month study
after the SP arm was completed, however it was not possible to
procure the drug and recently the drug has been withdrawn from
clinical development[26].
Participants
Symptomatic study in children aged 6–59 months. All
children between the ages 6 and 59 months who attended Hale
Health Centre during July–August 2006 with a fever or history of
fever during the study period were screened for malaria using a
rapid diagnostic test (RDT) (Paracheck, Orchid Biomedical
Systems, Verna, India). Children with a positive RDT had a
thick blood smear read and those with a positive blood smear were
referred to the study clinician. Study inclusion criteria were: (1)
weight of $4.5 kgs, (2) not -enrolled in the IPTi trial, (3) absence
of severe malnutrition (weight-for-height ,3 standard deviations
from the norm), (4) slide-confirmed infection with P. falciparum only
with an initial parasite density of between 2,000 and 200,000
asexual parasites per microliter, (5) absence of general danger signs
(inability to drink or breastfeed; vomiting; recent history of
convulsions; lethargy or unconsciousness; inability to sit or stand
up) or other signs of severe and complicated falciparum malaria
according to WHO definitions, (6) measured axillary temperature
$37.5uC, (7) ability to attend stipulated follow-up visits, (8)
informed consent provided by parent/guardian; (9) absence of
history of hypersensitivity reactions to SP and (10) no prior
antimalarial use in the preceding 2 weeks.
Asymptomatic study in children aged between 2 and
10 months. Consent was obtained from caretakers of 2–
10 month old infants who attended the Maternal Child Health
(MCH) clinic for immunization or weighing, for screening for P.
falciparum infection. From those consented for screening, finger
prick blood was obtained for the rapid diagnostic test, thick and
thin blood smear preparation and filter paper samples for
molecular studies. Children who had a positive blood slide were
further assessed for their eligibility for inclusion into the study and
enrolled in the drug sensitivity study after obtaining an informed
consent. The eligibility criteria were the same as for the study of
symptomatic children except that there was no history of fever in
the last 48 hours, that measured axillary temperature should be
less than 37.5uC and that the presence of P. falciparum parasitaemia
at any density was acceptable.
Sample size. In order to detect a 15% difference in adequate
parasite clearance by day 28 between symptomatic 6–59 month
old children and asymptomatic 2–10 month old children with
80% power at the 5% significance level using a ratio of 2
symptomatic cases to 1 asymptomatic case, we estimated that 292
symptomatic children and 146 asymptomatic infants would be
required.
Treatment allocation. Children were treated with SP
(FansidarH, Roche, France) by weight (1 tablet containing
500 mg sulfadoxine and 25 mg pyrimethamine; K tablet for
weights 4.5–10 kg, 1 tablet for 11–20 kg, 1K tablets for 21–
30 kg). The content and solubility of the SP tablets were confirmed
by solubility testing and high performance liquid chromatography
at the London School of Hygiene and Tropical Medicine. The
study drugs achieved the expected concentrations of SP in solution
when compared to controls (FansidarH, Roche, France) purchased
in the UK. SP was given under observation by study staff and
children were observed for at least 1 hour after treatment. If a
child vomited within 30 minutes of receiving the drug, the full
dose was repeated. if a child vomited between 30 minutes and an
hour, half the dose was repeated. If a study child vomited the study
medication twice, the study child was given rescue treatment and
excluded from the study. Rescue treatment for uncomplicated
malaria was artemether- lumefantrine (CoartemH, Novartis, Basel,
Swizterland) and for severe malaria was parenteral quinine.
Follow up. Children in the symptomatic study were seen at
the clinic on days 1, 2, 3, 7, 14, 21, and 28 after treatment and
dhps 581 G Mutation
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home visits were made for those who failed to report. Parents were
encouraged to bring any child who became ill between specified
visits to the clinic where they were evaluated and treated by a
study clinician thoughout the study period. Malaria blood films
and filter paper samples were obtained from children in the
symptomatic group at all active and passive follow-up time points.
Blood samples were not collected on days 1, 2, 3, and 21 from the
asymptomatic infants if the infant remained well. However, blood
samples were collected at any time if the infant became
symptomatic.
Endpoints. The primary end point, parasitological failure by
day 28 was defined as (1) development of danger signs or severe
malaria, (2) parasitaemia on Day 2 that was higher than that on
Day 0, (3) parasitaemia on Day 3$25% of the count on Day 0, (4)
parasitaemia on or after Day 4. Failures were further divided into
early treatment failures (within day 3 post treatment), late clinical
failures (recorded fever plus parasitaemia from day 4 to day 28
post treatment), and late parasitological failure (parasitaemia at
day 14 or day 28 post treatment in the absence of fever). In the
symptomatic study children with parasitaemia on or after day 4
were treated with rescue treatment if they became symptomatic or
until they reached day 28 when all parasitaemic children were
treated. In the asymptomatic study any child on or after day 4 with
parasitaemia was treated with rescue treatment.
Review of the prevalence of the A581G mutation in
Africa. The literature search for reports of the A581G
mutation up to October 2007 was done using the National
Library of Medicine search engines, Pubmed and Medline. The
following terms were included in the search queries: dhfr, dhps,
sulphadoxine, sulfadoxine, pyrimethamine, Fansidar, Africa,
prevalence, malaria and resistance. To be included in the
review, articles had to include analysis of codon 581 of the dhps
gene in isolates collected from study sites in Africa.
Laboratory Procedures. Blood smears were stained with
20% Giemsa for 20 minutes and read by two independent
microscopists for speciation, and quantification. Parasite density
was estimated by counting parasites against 200 White Blood Cells
(WBC). A blood smear was considered negative if no asexual forms
were seen after observing 500 WBC. Discordant results (33%
difference in quantification or positive/negative results) were read
by a third microscopist; agreement between any two micoscopists
and the average parasite density were deemed to be the correct
finding. Parasite counts were adjusted assuming a standard WBC
of 8000 per microlitre.
DNA was extracted from bloodspots dried on filter papers by
soaking overnight in 1 mL. of 0.5% saponin-16 phosphate
buffered saline (PBS). The segment was then washed twice in
1 ml of PBS and boiled for 8 min in 100 mL PCR quality water
with 50 mL 20% chelex suspension (pH 9.5). dhfr and dhps were
PCR amplified and point mutations at codons 51, 59, 108 and 164
of the dhfr gene and codons 436, 437, 540, 581, and 613 of the dhps
gene were genotyped using a dotblot methodology previously
described by Pearce et al[27]. The probed blots were visualised
through alkaline phosphatase-catalysed breakdown of the flouro-
genic substrate (ECF) (GE Healthcare, Buckinghamshire, UK) and
the chemifluorescent signal scanned on a TYPHOON TrioH
Phosphoimager (GE Healthcare, Buckinghamshire, UK). The
stringency and specificity of the hybridisation process was
confirmed by inspection of a series of four controls of known
single genotype variant sequence. All blots with non-specifically
bound probes were stripped and re-probed. A sequence variant
was considered to be present in the PCR product when the
intensity of signal was higher than that of the background. The
presence, absence, and relative abundance of hybridisation signal
was recorded for every probe at each locus. A sample was
considered to have a single haplotype when only one sequence
variant was found at each locus. Where alternative sequences were
present in the same these were designated as a mixed genotype
infection. Where mixture was detected at one locus only we
inferred a mixture of 2 haplotypes which varied only by that
codon.
We tested for the presence of mutations in addition to those at
codon 436, 437, 540, 581, and 613 of dhps by direct sequencing.
PCR products were purified using ExoSAP-ITH (USB Corpora-
tion, Cleveland, Ohio, USA). Cycle sequencing was performed
using Applied Biosystems BigDye V 3.1 and samples loaded on the
ABI-3730 capillary system. Sequence reads were checked by eye
and edited using the Seqman (DNAstar Inc., Madison, WI, USA).
The presence of SNPs was confirmed by reads through both
forward and reverse strands.
Recrudescent and new infections were differentiated first by
typing size and sequence of the highly polymorphic repeat region
of MSP2[28] and then by typing repeat length polymorphism at
the PfPK2 microsatellite marker[29]. The size polymorphism of
PCR amplified FC27 and IC1 fragments of MSP2, was
determined by agarose gel electrophoresis, stained with SYBRH
Green 1 (InvitrogenTM Ltd, Paisley, UK) and scanned on a
TYPHOON TrioH phosphoimager (GE Healthcare, Buckingham-
shire, UK). The gel image was analysed using ‘Imagequant
softwareTM’(Molecular Dynamics, Foster City, CA, USA) and
fragment sizes were calibrated to known fragment sizes in
HyperladderIV (BiolineTM, London, UK) which was run in
duplicate on every gel. Pre- and post-treatment samples for each
patient were compared according to sequence and size of the PCR
amplified MSP2 fragments. Recrudescent infections were charac-
terized as having at least one identical allele present in both pre
and post treatment samples. Matching alleles were defined as those
for which the analysis software estimated the sizes to be within
15 bp of each other. Samples where no alleles matched in the pre
and post treatment were classified as new infections. Pre-and post
treatment sample pairs which were classified as having a
recrudescent infection according to MSP2 matches were then
compared at the Pfpk2 microsatellite locus. The Pfpk2 micro-
sattelite repeat was pcr amplified using the protocol described in
Anderson et al[29] and fragments were run on an ABi 3730 DNA
analyzer (Applied Biosystems, Foster City, USA) with LIZ-500 size
standard and analyzed using Genemapper software (Applied
Biosystems, Foster City, USA). Any pairs of pre and post treatment
samples which matched at MSP2 but did not match at PfPK2
were re-classified as reinfections. If either pre or post sample failed
to amplify, they were classified as undetermined.
Multiplicity of infection (MoI) was assessed by examining the
numbers of alleles detected at MSP2 and pfPK2. Where the
number of alleles at these two loci differed, the higher of the two
values was used since this is the minimum number co-infecting
genotypes which can explain the observed diversity.
Statistical analysis. Data were double entered into an
Access (Microsoft Corps, Seattle, USA) data base and analyzed
in STATA 9.0 (Stata Corps,Texas, USA). Crude and PCR-
corrected rates (excluding new infections and indeterminate PCR)
were estimated. A survival analysis[30] was carried out by
censoring children at the time of a PCR-corrected new infection
or undetermined treatment failure and loss to follow up.
Logistic regression was used to determine factors associated with
treatment failures (cases) compared to non-failures (controls). The
following variables identified a priori were included in the logistic
regression model: age, parasite density, study population (asymp-
tomatic or symptomatic) and molecular markers. In addition, any
dhps 581 G Mutation
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factor that was significant at the 10% level in the crude analysis
was included in the model.
Further survival and regression analyses were carried out in
order to examine the relationship with time to failure and the
presence of the mutation 581G in the dhps gene.
Results
Response of symptomatic children and asymptomatic
infants to treatment with SP
One hundred and fifty, 6–59 month-old febrile children were
screened for malaria in July–August 2006 and 87 children who
fulfilled the inclusion criteria were enrolled (see figure 1).
Recruitment to the study arm was stopped early when the study
team observed an unacceptably high failure rate and 3 children
progressed to severe disease within 3 days post treatment with SP,
including one death due to severe malarial anaemia and
respiratory failure. No other adverse events were reported.
Between October 2006 and June 2007, 926 asymptomatic 2–
10 month-old infants were screened for malaria and 25 infants
with parasitaemia were enrolled into the study arm. This study was
also stopped early due to a high failure rate with one child
progressing to severe disease within 3 days post treatment. Apart
from this serious adverse event no other adverse events were
reported. The trial profiles are shown in figure 1. As expected, the
two study populations differed significantly in age, weight,
temperature and parasite density but not in mean haemoglobin
concentration (Table 1).
The therapeutic efficacy of SP by day 14 and 28 post treatment is
shown in Table 2. There was no statistically significant difference in
failure rates corrected by PCR for new infections between
symptomatic and asymptomatic groups by Day 14 (39% vs 53%;
p= 0.37) or Day 28 (82% vs 77%; p= 0.35). The survival analysis
(Figure 2) shows there was no significant difference between PCR
uncorrected results for the symptomatic and asymptomatic groups
in the time to treatment failure. When adjusted for the effect of age,
sex and parasite density at enrolment, the risk of treatment failure
was slightly higher in the symptomatic children compared to the
asymptomatic infants but this was not statistically significant (odds
ratio 1.2; 95% CI 0.55, 2.9; p= 0.6). Early Treatment Failures were
less common and Late Parasitological Failures were more common
in the asymptomatic group compared to symptomatic children
(table 2). There was no statistical difference between the prevalence
of new infections in either group (23% vs 11%, symptomatic and
asymptomatic groups respectively, p= 0.6).
Molecular findings
New infections were detected at all time periods in the study. In the
symptomatic group 4, 5 and 10 new infections were detected between
days 1–3, 4–14 and 15–28 respectively and in the asymptomatic
group 2 new infections were detected between days 4 and 14.
Molecular typing revealed a high rate of multiple clone infection both
Figure 1. Trial profiles. *Incomplete follow up on Day 14 (2 in symptomatic study, 1 asymptomatic study missed visit and were followed up at later
times).
doi:10.1371/journal.pone.0004569.g001
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pre and post treatment, with between 1–4 MSP2 alleles and 1–8
pfPK2 alleles found in individual infections. Figure 3 shows the
multiplicity of infection (MoI) by showing the mean number of
parasite clones present at enrolment, on the day of failure and the
mean number of clones in cases of recrudescence by week in the
study. Sixty-seven symptomatic treatment failures cases were
successfully analysed by both MSP2 and pfPK2. The mean number
of clones at enrolment and day of failure is constant throughout the 4
study weeks. At all times points there were multiple clones
recrudescing (treatment failures) in individual subjects. The mean
number of clones recrudescing was greatest in the first week of the
study and declined over time but remained greater than 1 for the
whole period. There were 5 examples where patients were found to
have between 5–6 identical pfPK2 alleles plus 2–3 MSP2 alleles
which matched on enrolment and day of failure, all occurred within
the first week of treatment.
The prevalence of mutations at each codon are shown in table 3
for dhfr and table 4 for dhps in both groups and prevalence of
haplotypes in table 5 for dhfr and dhps. There were no mutations
found at codon 164 in the dhfr gene but 54% of parasites in the
symptomatic group carried the 581 G mutation in the dhps gene on
enrollment day. The ratio of 581 G mutation to 581 A wild type
increased from enrollment day to day of failure (0.78 and 0.93
respectively) but this change was not statistically significant (p=0,5).
Direct sequencing confirmed the presence of mutations at codons
436, 437, 540 and 581 and did not reveal any additional mutations.
In the symptomatic group 96% of parasites carried the triple dhfr
mutant haplotype (mutants at codons 51, 59 and 108) (Table 4)
showing near saturation of this haplotype. As we would be unlikely to
demonstrate any further selection in dhfr haplotype we did not analyse
day of failure samples for these mutations in the symptomatic study.
Parasites with the double mutations in the dhps gene at codon
positions 437 and 540 were found in 65% and triple mutations with
the additional mutation at position 581 were found in 55% of samples
collected at enrolment. Molecular data for the asymptomatic study
were too few to analyze (6/25 samples amplified for the day of
enrolment) and were excluded from further analysis. From samples
from the symptomatic study a significant trend for increased and
earlier failure was seen with those carrying the 581G mutation prior
to treatment (Figure 4). However, in a regression model, factors
associated with failure in the symptomatic group were presence of
three mutations in the dhfr gene, age ,2 years and high parasite
density (Table 6) and not the presence of the 581 G mutations. The
results of the model did not change when looking at treatment failure
on or before day 3 versus failure after day 3 or treatment failure on or
before day 14 versus failure after day 14 (data not shown).
Distribution of the dhps position 581 mutation in Africa
We identified 107 surveys in 59 unique geographical localities in
Africa, where P. falciparum isolates have been tested for the 581G
mutation. The 41 references which describe them are listed in
supplementary online material (References S1). In addition to this
list a map with embedded survey details and links to the original
references is available online at www.drugresistancemaps.org.
The occurrence of the 581G mutation is comparatively rare in
both Tanzania (figure 5) and in Africa as a whole (figure 6). Of
4932 isolates tested in total, 96.5% carried the 581 A wild type
genotype. Survey sites where 581G mutations were not found are
identified in the maps as black circles whereas those in which
581G was found are shown as red circles with the prevalence of
the mutation indicated.
In Tanzania, the 581G mutation was observed in just 3 of 16
previous surveys. Our study in Hale found 581G in 54% of isolates
(n = 84). In Ifakara[31] in 1997, 27.8% of isolates (n = 18) were
found to carry the mutant while Mlimba[32] and Mbeya[33] had
low prevalence of 1.6% (n= 128) and 1.2% (n= 81) respectively.
Surveys in Butimba (n= 57), Mlimba (n= 59), Kyela (n = 67),
Masasi (n = 73), Mkuzi (n = 127), reported no 581G mutations [8],
and similarly a survey in Muheza (n= 28) [34].
In Africa as a whole the A581G mutation has been observed in
only 14 of a total of 106 surveys. The surveys that had observed
A581G mutation span nine countries namely Ethiopia[35] 1.6%
(n= 124), Ghana[36] 0.8% (n= 126), Kenya[31] 6.1% (n= 33),
Malawi[37] 3.4% (n= 89), Mali[31] 100% (n= 10) and 87%
(n= 8), Sudan [38]12.4% (n= 153), Tanzania (see above) and
Uganda[24,39,40] 11.5% (n= 122) and 45.8% (n= 72) 45%
(n= 60).
Discussion
The results of this study demonstrate clearly that use of SP for
the treatment of P falciparum malaria is dangerous in the area
where our study was done. SP had no effect on the course of illness
in four cases, three in the symptomatic group and one in the
asymptomatic group, who developed severe disease within 3 days
of post treatment. The efficacy of SP resulted in similarly poor
parasitologic clearance in 2–10 month old asymptomatic infants
when compared with 6–59 month old symptomatic children. The
WHO recommends changing first line treatment when day 28
failure rates exceed 10%[9]. In this study, early treatment failures
of symptomatic children were 38.8% and by day 28 a staggering
82% required rescue treatment. Shortly after the study was
stopped artemether-lumefantrine (ALU) became the first-line
treatment for uncomplicated malaria in Tanzania, although SP
remains widely available through private drug stores and is
frequently used.
The primary purpose of this study was to determine if SP was
more efficacious in asymptomatic parasitaemic infants than in
symptomatic children even though the drug was failing as a
treatment for the latter group. This has been shown to be the case
Table 1. Baseline characteristics of the two study populations.
Parameter Symptomatic children (N=87) Asymptomatic infants (N=25) P value
Mean age (months, SD) 31.1 (13.3) 7.1 (2.2) ,0.001
Mean weight (Kg, SD) 11.9 (2.3) 7.6(1.0) ,0.001
Mean haemoglobin (g/dl, SD) 9.04 (1.9) 8.6 (1.1) 0.353
Mean temperature (uC, SD) 38.5 (3.2) 36.7 (0.32) 0.005
Temperate Range (uC) 37.5–40.9 36.0–37.5 ,0.001
Geometric mean density (asexual forms/mL) 13,914 4,173 ,0.001
doi:10.1371/journal.pone.0004569.t001
dhps 581 G Mutation
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for pregnant women in areas of moderate SP resistance where SP
may still be effective for treatment or prevention even though it
fails when used for the treatment of symptomatic children[41,42].
Because the study had to be terminated prematurely on the
grounds of the unexpectedly high failure rates in symptomatic
children and asymptomatic infants, it was underpowered to show a
difference between the two study groups. Estimates of efficacy had
confidence intervals of 10% and 20% in the symptomatic and
asymptomatic study groups respectively and the study was
powered to detect only a 30% or more difference between groups.
Nevertheless, the findings suggest that there was no major
difference in response to SP between symptomatic older children
and asymptomatic infants contrasting with the major differences
observed in comparisons between asymptomatic pregnant women
and symptomatic children. This difference may be due to the fact
that infants in the second half of the first year of life, in contrast to
pregnant women, have less naturally acquired immunity to
malaria. In pregnant women, but not infants, naturally acquired
immunity may be sufficient to clear low density infections when
parasites are exposed to an only partially effective drug. Evidence
from high transmission sites suggests that maternal protective
factors do protect infants against recrudescence[43,44], however,
Figure 2. Cumulative proportion of treatment failures of Sulphadoxine-Pyrimethamine in symptomatic 6–59 month and
asymptomatic 2–10 month old children with malaria.
doi:10.1371/journal.pone.0004569.g002
Figure 3. Comparison of Multiplicity of Infection (MoI) at enrolment and at day of failure and the mean MoI in cases of
recrudescence by week of failure. LEGEND: 67 symptomatic treatment failures cases were successfully analysed by both MSP2 and pfPK2 and
were sorted according to week of failure post treatment. White bars show the mean multiplicity of infection (MoI) at enrolment. Grey bars show the
MoI on the day of treatment failure. Black bars show the mean number of matching alleles in the pre and post treatment sample of each patient
(N = 49 after exclusion of those defined as new infections).
doi:10.1371/journal.pone.0004569.g003
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how these protective factors compare to maternal immunity itself
is not known. Although the study split children into symptomatic
and asymptomatic groups the difference between these groups
may only be that the asymptomatic children were at an earlier
stage of the disease. In children in a moderate transmission setting
in Uganda approximately 50% of asymptomatic parasitaemic
children progressed to clinical disease within 30 days of detec-
tion[45]. This group of children, however, is relevant for this study
as they represent the population who would be treated with IPTi.
This study examined the treatment effect of SP and did not
address the ability for SP to prevent blood stage infection, i.e. the
prophylactic effect[10]. Whether SP has any efficacy in the study
area when used for IPTi (both treatment and prophylactic
effects[10]) will be determined in an ongoing IPTi study that will
be reported in early 2009 (clintrial.gov identifier: NCT00158574).
Within 8 years the level of SP resistance in the study area has
increased at an alarming rate. The day 28 ACPR has decreased
from 55% in 1999 [34] to the current situation of 18%. This
change is likely to have been driven, at least in part, by the use of
SP as first line treatment for malaria from 2001 to 2007. Now that
first line treatment for malaria has changed to combination
therapy across most of sub- Saharan Africa, the selection pressure
for resistance to SP will have been reduced. Nevertheless the rapid
increase in SP resistance is a concern and an alternative drug
needs to be developed for all SP-based prevention programs.
The molecular work was limited by the number of clones in the
samples and the sensitivity of the methods to detect masked clones.
In the symptomatic group 4 new infections were detected in the
first 3 days post-treatment. This is a highly unlikely result and is
probably due to masked clones resistant to SP becoming dominant
post treatment, a common criticism of PCR-correction. This
problem was also likely to interfere with the interpretation of new
infections when comparing the symptomatic and asymptomatic
groups as the symptomatic group was more likely to have heavier
Table 3. Prevalence of mutations in dhfr gene at day of enrolment and day of failure in all study children.
Enrolment day symptomatic cases Day of failure symptomatic cases
N=84
codon 51 59 108 164 51 59 108 164
sensitive N C S I Not done Not done Not done Not done
9 (10.7%) 11 (13.1%) 3 (3.6%) 84 (100%)
mutant I R N L Not done Not done Not done Not done
81 (96.4%) 79 (94.0%) 82 (97.6%) 0 (0%)
Enrolment day asymptomatic cases Day of failure asymptomatic cases
N=6 N=6
codon 51 59 108 164 51 59 108 164
sensitive N C S Not done N C S Not done
4 (66.7%) 2 (33.3%) 2 (33.3%) 0 (0%) 0 (0%) 0 (0%)
mutant I R N Not done I R N Not done
5 (83.3%) 6 (100%) 6 (100%) 6 (100%) 6 (100%) 6 (100%)
doi:10.1371/journal.pone.0004569.t003
Table 4. Prevalence of mutations in dhps gene at day of enrolment and day of failure in all study children.
Enrolment day symptomatic cases Day of failure symptomatic cases
N=87 N=67
codon 436 437 540 581 613 436 437 540 581 613
sensitive S A K A A S A K A A
85 (97.7%) 13 (14.9%) 14 (16.1%) 60 (69.0%) 87 (100%) 67 (100%) 3 (4.5%) 3 (4.5%) 44 (65.7%) 67 (100%)
mutant A,C,F G E G S,T A,C,F G E G S,T
8 (9.2%) 83 (95.4%) 82 (94.3%) 47 (54.0%) 0 (0%) 1 (1.5%) 67 (100%) 67 (100%) 41 (61.2%) 0 (0%)
Enrolment day asymptomatic cases Day of failure asymptomatic cases
N=9 N=11
codon 436 437 540 581 613 436 437 540 581 613
sensitive S A K A A S A K A A
9 (100%) 0 (0%) 1 (11.1%) 7 (77.8%) 9 (100%) 11 (100%) 0 (0%) 0 (0%) 8 (72.7%) 11 (100%)
mutant A,C,F G E G S,T A,C,F G E G S,T
0 (0%) 9 (100%) 9 (100%) 4 (44.4%) 0 (0%) 0 (0%) 11 (100%) 11 (100%) 6 (54.5%) 0 (0%)
doi:10.1371/journal.pone.0004569.t004
dhps 581 G Mutation
PLoS ONE | www.plosone.org 8 February 2009 | Volume 4 | Issue 2 | e4569
parasite densities and more clones. Thus, in the symptomatic
group a higher proportion of recrudescences would be wrongly
called new infections. The number of clones detected in samples
was high and in many cases these represented multiple clones
recrudescing reflecting the high transmission and high prevalence
of resistance genotypes circulating in the study area.
Further in vivo efficacy studies of SP are unjustifiable in areas
where the level of SP resistance is known to be high. In such
situations, studies of molecular markers of resistance play a key
role in measuring patterns of resistance as there is strong evidence
that mutations in dhfr and dhps genes are associated with P.
falciparum resistance to SP. Previous reports from Africa have
demonstrated an association between moderate levels of resistance
to SP and triple mutation in the dhfr [16,17,18] and double
mutations in the dhps genes[18] and this association was found in
our study. In South East Asia the presence of high level resistance
to antifolates has been associated with the presence on an
additional mutation at position 164 on the dhfr gene[20]. In the
face of the very high level of SP resistance found in Hale we
considered it possible that parasites carrying this mutation had
emerged in north-eastern Tanzania. However, this did not turn
out to be the case and no parasites carrying the 164 mutation were
found. Instead 55% of haplotypes, when they could be
ascertained, in addition to the 437 and 540 mutations had a
mutation at codon 581 in the parasite dhps gene and there was
some evidence that the presence of this mutation in parasites at the
start of treatment was associated earlier treatment failure.
Biological plausibility of this is backed by the findings that the
581G single mutant offers resistance in vitro and that similar
mutations in bacteria produce resistance to sulfa drugs[14]. The
dhps triple is recognized in South America, where it is associated
with SP treatment failure[46]. Parasites carrying the 581G
mutation are widely distributed in Tanzania (figure 5) and
elsewhere in Africa (figure 6). The evidence of prevalence of this
mutation is patchy with few studies looking at this locus and those
that have show considerable differences in prevalence between
countries. It is likely that the large drug pressure caused when SP
was the first line drug for uncomplicated malaria that has driven
the rise in frequency of first the dhps double and now the more
resistant dhps triple mutation. This early failure may prove to be
pertinent in the case of IPTp. ter Kuile and colleagues[41] found
that SP IPTp had reasonable protective efficacy against low birth-
weight even in areas where the day 14 treatment failure rate of SP
in symptomatic children was as high as 35%. However, they
observed that the duration of prophylaxis of SP had reduced from
4 to 2 weeks. In areas where the 581 mutation is present in
conjunction with the triple dhfr and double dhps mutants, it is
Table 5. Prevalence of point mutation haplotypes in dhfr and
dhps at day of enrolment in symptomatic and asymptomatic
children.
Number of samples N=84*
dhfr mutations
Sensitive (NCS) 3 (3.6%)
Single (NCN) 0 (0%)
Double (ICN) 8 (9.5%)
Double (NRN) 1 (1.2%)
Triple (IRN) 81 (96.4%)
Mixed infections (unable to determine haplotype) 0 (0%)
Number of samples N=87*
dhps mutations
Sensitive (SAKA) 4 (4.6%)
Single (436A or C only =AAKA or CAKA) 8 (9.2%)
Single (437G only = SGKA) 0 (0%)
Single (540E only = SAEA) 0 (0%)
Single (581G only = SAKG) 1 (1.1%)
Double (437G+540E only = SGEA) 55 (63.2%)
Triple (437G+540E+581G= SGEG) 48 (55.2%)
Mixed infections (unable to determine haplotype) 2 (2.3%)
*includes mixed infections when haplotypes could be ascertained (9 for dhfr
and 31 for dhps).
doi:10.1371/journal.pone.0004569.t005
Figure 4. Cumulative proportions of treatment failure of Sulphadoxine-Pyrimethamine in symptomatic 6–59 month old children
with malaria parasites carrying or not-carrying the A581G mutation in the dhps gene at enrolment. Unadjusted effect dhps gene
mutation at 581, p-value= 0.012.
doi:10.1371/journal.pone.0004569.g004
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Table 6. Association between mutations and treatment failure.
Parameter Category Total (n) All failures (%) Crude OR Adjusted OR* P-value
dhfr mutation No/single/double 6 3 1.0 1.0
Triple 72 66 11.0 (1.8–66.9) 12.0 (1.1–128) 0.040
dhps A581G mutation No mutation 36 28 1.0 1.0
Mutation 43 40 3.8 (0.9–15.6) 4.9 (0.7–34.8) 0.116
Age ,2 yrs 29 27 1.0 1.0
2–4 yrs 56 45 0.4 (0.1–1.8) 0.04 (0.002–0.9) 0.046
Parasite density (Asexual forms/ul) ,28000 29 21 1.0 1.0
(28000–67000) 27 26 9.9(1.1–85.6) 20.5(1.2–330) 0.033
.68000 7 25 4.8(0.9–4.9) 10.4(1.1–95.8) 0.039
Adjusted odds ratio: logistic regression model including age, parasite density and mutations of DHFR and DHPS. Asymptomatic cases not included in model due to too
few cases with complete molecular results (6/25).
doi:10.1371/journal.pone.0004569.t006
Figure 5. Distribution of 581G mutation in Tanzania.
doi:10.1371/journal.pone.0004569.g005
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possible that the duration of prophylaxis given by SP will be
further reduced and this may affect the protective efficacy of SP
preventative strategies. Further work is needed to determine the
geographical spread of this mutant and if the presence of this
mutation in combination with the dhfr triple and dhps double
confers increased and earlier failure of cases treated with SP.
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